| abstract |
Treatment or prevention of OAB or UI in mammals, particularly humans, is disclosed using NK2R binding compounds in accord with structural diagram (I) wherein A, R?1, R2, R3 and R4¿ are as defined in the specification. Pharmaceutically-advantageous salts of the compounds, methods of use of the compounds, either alone or in combination with other pharmacological agents, and pharmaceutical compositions useful in practicing the methods of the invention are also disclosed. |